Abstract
Background
It is currently thought that pulmonary embolism and deep vein thrombosis are different manifestations of the same pathological process of venous thromboembolism. Venous thromboembolism has a negative correlation with high‐density lipoprotein cholesterol.
Hypothesis
Pulmonary embolism has a negative correlation with the level of high‐density lipoprotein cholesterol.
Methods
A total of 90 patients with pulmonary embolism, diagnosed and treated at a single center, were retrospectively analyzed for the present study. Among them were 57 cases of pulmonary arterial trunk embolism in group A and 33 cases of pulmonary arterial non‐trunk embolism in group B.
Results
The results showed that the level of high‐density lipoprotein cholesterol decreased markedly in patients with pulmonary arterial trunk embolism as compared to those with pulmonary arterial non‐trunk embolism. A stepwise logistic regression analysis was performed upon the relationship between pulmonary arterial trunk embolism and multiple factors. The results showed that a pulmonary arterial trunk embolism had a negative correlation with the level of high‐density lipoprotein cholesterol and a positive correlation with triglyceride and high sensitivity C‐reactive protein.
Conclusions
Pulmonary arterial trunk embolism is negatively correlated with the level of high‐density lipoprotein cholesterol. Copyright © 2010 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (119.1 KB).
References
- 1. Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta‐analysis. Circulation 2008; 117: 93–102. [DOI] [PubMed] [Google Scholar]
- 2. Deguchi H, Natalie M. Pecheniuk NM, et al. High‐density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112: 893–899. [DOI] [PubMed] [Google Scholar]
- 3. González‐Ordóñez AJ, Fernández Carreira JM, Fernández‐Alvarez CR, et al. The concentrations of soluble vascular cell adhesion molecule‐1 and lipids are independently associated with venous thromboembolism. Haematologica 2003; 88(9): 1035–1043. [PubMed] [Google Scholar]
- 4. Ay C, Tengler T, Vormittag R, et al. Venous thromboembolism—a manifestation of the metabolic syndrome. Haematologica 2007; 92: 374–380. [DOI] [PubMed] [Google Scholar]
- 5. Eichinger S, Pecheniuk NM, Hron G, et al. High‐density lipoprotein and the risk of recurrent venous thromboembolism. Circulation 2007; 115: 1609–1614. [DOI] [PubMed] [Google Scholar]
- 6. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435–1441. [DOI] [PubMed] [Google Scholar]
- 7. Hong C, Zhu F, Du D, et al. Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis 2005; 183: 169–174. [DOI] [PubMed] [Google Scholar]
- 8. Becattini C, Agnelli G, Prandoni P, et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005; 26(1): 77–83. [DOI] [PubMed] [Google Scholar]
- 9. Naqvi TZ, Shah PK, Ivey PA, et al. Evidence that high‐density lipoprotein cholesterol is an independent predictor of acute platelet‐dependent thrombus formation. Am J Cardiol 1999; 84: 1011–1017. [DOI] [PubMed] [Google Scholar]
- 10. Li D, Weng S, Yang B, et al. Inhibition of arterial thrombus formation by apoA1 milano. Arterioscler Thromb Vasc Biol 1999; 19: 378–383. [DOI] [PubMed] [Google Scholar]
- 11. Duncan BB, Schmidt MI, Chambless LE, et al. Fibrinogen, other putative markers of inflammation, and weight gain in middle‐aged adults: the ARIC study: atherosclerosis risk in communities. Obes Res 2000; 8: 279–286. [DOI] [PubMed] [Google Scholar]
- 12. Doggen CJ, Smith NL, Lemaitre RN, et al. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 1970–1975. [DOI] [PubMed] [Google Scholar]
- 13. Englyst NA, Taube JM, Aitman TJ, et al. A novel role for CD36 in VLDL‐enhanced platelet activation. Diabetes 2003; 52: 1248–1255. [DOI] [PubMed] [Google Scholar]
- 14. Suc I, Escargueil‐Blanc I, Troly M, et al. HDL and apoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol 1997; 17: 2158–2166. [DOI] [PubMed] [Google Scholar]
- 15. Sugano M, Tsuchida K, Makino N. High‐density lipoproteins protect endothelial cells from tumor necrosis factor‐alpha‐induced apoptosis. Biochem Biophys Res Commun 2000; 272: 872–876. [DOI] [PubMed] [Google Scholar]
- 16. Spieker LE, Sudano I, Hürlimann D, et al. High‐density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105(12): 1399–1402. [DOI] [PubMed] [Google Scholar]
- 17. Li XP, Zhao SP, Zhang XY, et al. Protective effect of high density lipoprotein on endothelium‐dependent vasodilatation. Int J Cardiol 2000; 73(3): 231–236. [DOI] [PubMed] [Google Scholar]
- 18. Gong M, Wilson M, Kelly T, et al. HDL‐associated estradiol stimulates endothelial NO synthase and vasodilation in an SR‐BI‐dependent manner. J Clin Invest 2003; 111(10): 1579–1587. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Wadham C, Albanese N, Roberts J, et al. High‐density lipoproteins neutralize C‐reactive protein proinflammatory activity. Circulation 2004; 109: 2116–2122. [DOI] [PubMed] [Google Scholar]
- 20. Koyama H, Maeno T, Fukumoto S, et al. Platelet P‐selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation 2003; 108: 524–529. [DOI] [PubMed] [Google Scholar]
- 21. Griffin JH, Kojima K, Banka CL, et al. High‐density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103: 219–227. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Nicholls SJ, Cutri B, Worthley SG, et al. Impact of short‐term administration of high‐density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 2005; 25: 2416–2421. [DOI] [PubMed] [Google Scholar]
- 23. Yang CC, Kao CC. Cardiovascular diseases and the risk of venous thromboembolism: a hospital‐based case‐control study. J Chin Med Assoc 2007; 70(3): 103–109. [DOI] [PubMed] [Google Scholar]
- 24. Li D, Weng S, Yang B, et al. Inhibition of arterial thrombus formation by apoA1 milano. Arterioscler Thromb Vasc Biol 1999; 19: 378–383. [DOI] [PubMed] [Google Scholar]
- 25. Kurl S, Laukkanen JA, Niskanen L, et al. Metabolic syndrome and the risk of stroke in middle‐aged men. Stroke 2006; 37: 806–811. [DOI] [PubMed] [Google Scholar]
- 26. Milionis HJ, Rizos E, Goudevenos J, et al. Components of the metabolic syndrome and risk for first‐ever acute ischemic nonembolic stroke in elderly subjects. Stroke 2005; 36: 1372–1376. [DOI] [PubMed] [Google Scholar]
- 27. Kastelein JP, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356(16): 1620–1630. [DOI] [PubMed] [Google Scholar]